Condition (MeSH)
Histiocytosis, Langerhans-Cell
ClinicalTrials.gov lists 79 trials for Histiocytosis, Langerhans-Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 15.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
79 of the 79 trials are tagged with Histiocytosis, Langerhans-Cell itself; the rest are tagged with a narrower condition beneath it.
When did Histiocytosis, Langerhans-Cell trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 9 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 6 |
| 2017 | 9 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 57 months across 36 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Histiocytosis, Langerhans-Cell trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 3 |
| Phase 2 | 43 |
| Phase 2/3 | 3 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 5 |
| Observational | 15 |
How many Histiocytosis, Langerhans-Cell trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 17 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 20 |
| Completed | 21 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Histiocytosis, Langerhans-Cell trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 15 |
| Novartis Pharmaceuticals | 2 |
Which drugs are being tested for Histiocytosis, Langerhans-Cell? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Melphalan | 6 |
| GSK1120212 | 5 |
| Cytoxan | 5 |
| Busulfan | 5 |
| CLOFARABINE | 4 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 6 |
| Cytarabine IT | 5 |
| Positron Emission Tomography (PET) | 5 |
| Vermurafenib | 4 |
| Bone scan | 4 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Histiocytosis, Langerhans-Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 22 | 1 |
| Disease progression | 16 | 8 |
| Neutrophil count decreased | 14 | 5 |
| Anemia | 13 | 2 |
| Platelet count decreased | 10 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Histiocytosis, Langerhans-Cell? (96)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. | Blood | 2025 | Yes |
| Chronic health conditions after childhood Langerhans cell histiocytosis: Results from the Swiss Childhood Cancer Survivor Study. | Journal of cancer survivorship : research and practice | 2025 | Yes |
| Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads. | Blood | 2025 | Yes |
| Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. | Haematologica | 2024 | Yes |
| Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. | British journal of haematology | 2024 | Yes |
Showing 5 of 96 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Langerhans cell histiocytosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Langerhans cell histiocytosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Langerhans cell histiocytosis | 389 | Exact | Orphadata Science knowledge files, Product 1 |
| Langerhans cell histiocytosis | 389 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.